[1] 侯帅, 樊琳琳, 戴光荣. 非手术治疗原发性肝癌研究进展. 实用肝脏病杂志, 2016, 19: 249-252. [2] Tsurusaki M, Murakami T. Surgical and Locoregional Therapy of HCC: TACE. Liver Cancer, 2015, 4: 165-175. [3] Pinato DJ, Howell J, Ramaswami R. Review article: delivering precision oncology in intermediate-stage liver cancer.Aliment Pharmacol Ther, 2017, 45: 1514-1523. [4] 郭兴军, 郑艳红, 关强. 肝动脉化疗栓塞联合射频消融术治疗原发性肝癌的疗效分析. 实用临床医药杂志, 2015, 19: 44-47. [5] Giorgio A, Merola MG, Montesarchio L, et al. Percutaneous radiofrequency ablation (RFA) of hepatocellular carcinoma (HCC) in cirrhosis: analysis of complicationsin a single center over 20 years. Br J Radiol, 2017, 90: 20160804. [6] Na BG, Kim JM, Oh DK, et al. Clinical outcomes of laparoscopic radiofrequency ablation of single primary or recurrent hepatocellular carcinoma (≤3 cm). Ann Surg Treat Res,2017, 92: 355-360. [7] 崔贤杰,范春花,汤小玉.雷替曲塞在TACE治疗中晚期原发性肝癌中疗效观察.现代仪器与医疗,2016,22: 113-114, 117. [8] 郝锐, 郑雪松, 邵旭辉. 肝癌TACE与RFA治疗前后ICG R15及肝功能变化. 中国城乡企业卫生, 2016, 31: 121-122. [9] 王文辉, 刘武, 段廷旺, 等. TACE联合RFA治疗原发性肝癌的疗效观察. 中国医药指南, 2015,13: 13-15. |